Tvardi Therapeutics (TVRD) Price & Analysis

Compare

2,538 Followers

TVRD Stock Chart & Stats

$3.94

Market closed

$3.94

Day’s Range― - ―

52-Week Range$5.65 - $43.65

Previous CloseN/A

VolumeN/A

Average Volume (3M)401.55K

Market Cap

$41.17M

Enterprise Value$156.52M

Total Cash (Recent Filing)$40.99M

Total Debt (Recent Filing)$254.00K

Price to Earnings (P/E)―

Beta0.44

Next Earnings

May 12, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-46.64

Shares Outstanding9,377,433

10 Day Avg. Volume1,070,842

30 Day Avg. Volume401,545

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap3.80

Enterprise Value/Revenue23.79

Enterprise Value/Gross Profit24.39

Enterprise Value/Ebitda-5.85

Forecast

1Y Price Target

$16.00

Price Target Upside306.09% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Drug DevelopmentTTI-109, a pro-drug of TTI-101, has a higher bioavailability and is expected to have improved tolerability by reducing GI-related adverse events, which could be significant.

Market ExpansionManagement plans to assess the opportunity to expand TTI-109 into other STAT3-driven indications following the completion of the TTI-109 HV study.

Therapeutic PotentialThere is potential for broad therapeutic relevance with safe STAT3 inhibition, including anti-fibrotic activity that could address several diseases with high unmet need.

Bears Say

Financial ValuationThe analyst is raising the discount rate to 20.0% and lowering the price target from $55 to $15.

Trial ResultsPreliminary REVERT-IPF results show no discernible benefit on FVC decline and higher discontinuation rates primarily attributed to GI-related adverse events for TTI-101 compared to placebo.

Tvardi Therapeutics News

Tvardi downgraded to Market Perform from Outperform at Raymond James

Raymond James downgraded Tvardi Therapeutics (TVRD) to Market Perform from Outperform without a price target The firm believes...

25d ago

TVRD

Tvardi Therapeutics downgraded to Equal Weight from Overweight at Barclays

Barclays downgraded Tvardi Therapeutics (TVRD) to Equal Weight from Overweight with a price target of $5, down from...

25d ago

TVRD

Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!

Traders looking for the top stock market stories on Monday will find them in TipRanks’ daily wrap-up. ...

26d ago

AMD

Cantor downgrades Tvardi Therapeutics, sees ‘no path forward in IPF’

As previously reported, Cantor Fitzgerald downgraded Tvardi Therapeutics (TVRD) to Neutral from Overweight after the company provided an...

26d ago

TVRD

Tvardi Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

Cantor Fitzgerald downgraded Tvardi Therapeutics (TVRD) to Neutral from Overweight. Published first on TheFly – the ultimate source...

26d ago

TVRD

Tvardi Therapeutics downgraded to Neutral from Overweight at Piper Sandler

Piper Sandler analyst Yasmeen Rahimi downgraded Tvardi Therapeutics (TVRD) to Neutral from Overweight with a price target of...

26d ago

TVRD

Morning Movers: Bloom Energy surges following $5B investment from Brookfield

A volatile weekend in trade relations and tactical messaging is fueling renewed market caution, though stock futures are...

26d ago

Why Is Tvardi Therapeutics Stock (TVRD) Down 85% Today?

Tvardi Therapeutics stock dove after the company reported results from a recent clinical trial. ...

26d ago

TVRD

Tvardi says benefit of TTI-101 treatment not observed in REVERT trial

Tvardi Therapeutics (TVRD) provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101...

26d ago

TVRD

Tvardi Therapeutics initiated with an Overweight at Barclays

Barclays analyst Etzer Darout initiated coverage of Tvardi Therapeutics (TVRD) with an Overweight rating and $61 price target...

26d ago

TVRD

Tvardi Therapeutics’ Liver Cancer Study: A Potential Game-Changer?

Tvardi Therapeutics Inc. (($TVRD)) announced an update on their ongoing clinical study. Tvardi Therapeutics Inc. is conducting a...

11d ago

TVRD

Tvardi Therapeutics Faces Setback in Phase 2 Trial

The latest update is out from Tvardi Therapeutics ( ($TVRD) ). On October 13, 2025, Tvardi Therapeutics provided...

25d ago

TVRD

Optimistic Buy Rating for Tvardi Therapeutics: Promising Potential of TTI-109 Amidst TTI-101 Setbacks

Julian Harrison, an analyst from BTIG, maintained the Buy rating on Tvardi Therapeutics. The associated price target is...

25d ago

TVRD

BTIG biotech analyst holds a dinner meeting

Biotech Analyst Harrison holds a dinner meeting with Tvardi Therapeutics (TVRD) to discuss Emerging Trends in Pulmonary Fibrosis...

1M ago

TVRD

TVRD FAQ

What was Tvardi Therapeutics’s price range in the past 12 months?

Tvardi Therapeutics lowest stock price was $5.65 and its highest was $43.65 in the past 12 months.

What is Tvardi Therapeutics’s market cap?

Tvardi Therapeutics’s market cap is $41.17M.

When is Tvardi Therapeutics’s upcoming earnings report date?

Tvardi Therapeutics’s upcoming earnings report date is May 12, 2025 which is 180 days ago.

How were Tvardi Therapeutics’s earnings last quarter?

Currently, no data Available

Is Tvardi Therapeutics overvalued?

According to Wall Street analysts Tvardi Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tvardi Therapeutics pay dividends?

Tvardi Therapeutics does not currently pay dividends.

What is Tvardi Therapeutics’s EPS estimate?

Tvardi Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Tvardi Therapeutics have?

Tvardi Therapeutics has 9,377,433 shares outstanding.

What happened to Tvardi Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Tvardi Therapeutics?

Currently, no hedge funds are holding shares in TVRD

Tvardi Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-93.85%

Trailing 12-Months

Asset Growth

-39.65%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tvardi Therapeutics

Tvardi Therapeutics (TVRD) is a biotechnology company focused on the development of innovative therapeutic solutions for cancer and other serious diseases. The company specializes in the discovery and advancement of small molecule drugs aimed at targeting specific pathways involved in disease progression. Tvardi's core product pipeline includes novel compounds that are designed to inhibit key proteins, thereby offering potential new treatments for various types of cancer and other conditions.

Tvardi Therapeutics (TVRD) Earnings & Revenues

Historic Earnings Reports

TVRD Stock 12 Month Forecast

Average Price Target

$16.00

▲(306.09% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","14":"$14","25":"$25","36":"$36","47":"$47"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$46.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,14,25,36,47],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.65,7.830769230769231,11.011538461538462,14.192307692307693,17.373076923076923,20.553846153846155,23.734615384615388,26.915384615384617,30.096153846153847,33.276923076923076,36.45769230769231,39.63846153846154,42.81923076923077,{"y":46,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.65,5.523076923076923,6.3961538461538465,7.26923076923077,8.142307692307693,9.015384615384615,9.888461538461538,10.761538461538462,11.634615384615385,12.507692307692308,13.38076923076923,14.253846153846155,15.126923076923077,{"y":16,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.65,4.6000000000000005,4.550000000000001,4.5,4.45,4.4,4.3500000000000005,4.3,4.25,4.2,4.15,4.1,4.05,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.77,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.69,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.47,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18.36,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.34,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.82,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.76,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.58,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.65,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >